Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talsaclidine Efficacy and Safety in Mild to Moderate Alzheimer's Disease
NCT02249403Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 1999
- Primary completion
- Jan 2000
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of talsaclidine in Alzheimer's disease (AD), sponsored by Boehringer Ingelheim. Started Jan 1999; status: completed.
02
Drugs
talsaclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02249403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249403.